Table 5.
Correlates of Increasing Multimorbidity Among ALIVE Study Participants (N = 1262)
Unadjusted OR (95% CI)a | P value | Adjusted OR (95% CI)a | P value | |
Age (per 1-year increase) | 1.06 (1.04–1.07) | <.001 | 1.06 (1.04–1.07) | <.001 |
Sex | ||||
Male | ref | ref | ||
Female | 1.10 (.890–1.35) | .388 | 1.29 (1.04–1.60) | .023 |
Race | ||||
White/Other | ref | |||
African-American | 1.86 (1.37–2.53) | <.001 | ||
Marital statusb | ||||
Never married | ref | |||
Ever married | 1.22 (0.989–1.50) | .064 | ||
Employedc | ||||
No | ref | |||
Yes | 0.941 (.744–1.19) | .612 | ||
Homelessc | ||||
No | ref | |||
Yes | 0.813 (.615–1.07) | .144 | ||
Cigarette smokerc | ||||
No | ref | ref | ||
Yes | 0.599 (.458–.784) | <.000 | 0.697 (.527–.923) | .012 |
No. alcoholic drinks/dayc | ||||
0 | ref | |||
1–2 | 0.734 (.579–.930) | .011 | ||
3–4 | 0.770 (.575–1.03) | .079 | ||
≥5 | 1.00 (.695–1.45) | .981 | ||
Drug userc | ||||
No | ref | ref | ||
Noninjection only | 0.639 (.483–.845) | .002 | 0.672 (.502–.900) | .008 |
Injection only | 0.652 (.481–.883) | .006 | 0.753 (.550–1.03) | .075 |
Both | 0.478 (.371–.616) | <.001 | 0.600 (.458–.787) | <.001 |
Depressive symptoms | ||||
CES-D <23 | ref | ref | ||
CES-D ≥23 | 1.18 (.926–1.50) | .180 | 1.44 (1.11–1.85) | .005 |
HIV status | ||||
HIV negative | ref | ref | ||
HIV positive | 1.99 (1.60–2.49) | <.001 | 1.50 (1.13–1.99) | .005 |
Current CD4 T-cell countd | 1.11 (1.03–1.20) | .007 | ||
CD4 T-cell nadird | 1.18 (1.04–1.34) | .003 | 1.14 (1.00–1.29) | .046 |
HIV log10 HIV RNAe | 1.19 (0.988–1.44) | .067 | 1.32 (1.08–1.60) | .006 |
Abbreviations: ALIVE, AIDS Linked to the IntraVenous Experience study; CES-D, Center for Epidemiologic Studies Depression Scale; CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio.
Univariate and multivariate proportional odds model: Under the proportional odds assumption, the estimated OR applies to any of the 3 ORs being modeled; that is, we estimate the OR for ≥1 conditions relative to 0, the OR for ≥2 conditions relative to 0–1, or the OR for ≥3- conditions relative to 0–2.
At enrollment.
In prior 6 months.
Per 100-cell decrease (centered at 200 cells/mm3).
Per log10 copies/mL increase (centered at 2.60, level of detection).